Teva Pharmaceutical Industries Limited (NYSE:TEVA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Teva Pharmaceutical Industries Limited (NYSE:TEVA) has been assigned an average rating of “Moderate Buy” from the seven analysts that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $23.57.

A number of research analysts have issued reports on TEVA shares. StockNews.com downgraded Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. Piper Sandler boosted their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a report on Friday, January 17th. UBS Group decreased their price target on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a report on Thursday, January 30th. Finally, Barclays decreased their price target on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a report on Thursday, January 30th.

Insider Activity

In other news, Director Roberto Mignone sold 286,000 shares of the business’s stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $22.01, for a total value of $6,294,860.00. Following the completion of the sale, the director now directly owns 695,000 shares in the company, valued at $15,296,950. The trade was a 29.15 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.55% of the company’s stock.

Institutional Trading of Teva Pharmaceutical Industries

Large investors have recently made changes to their positions in the company. Oarsman Capital Inc. purchased a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter worth approximately $29,000. Marshall & Sterling Wealth Advisors Inc. purchased a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter worth approximately $44,000. Smithfield Trust Co increased its position in shares of Teva Pharmaceutical Industries by 55.7% during the third quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock worth $50,000 after purchasing an additional 980 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in shares of Teva Pharmaceutical Industries during the third quarter worth approximately $50,000. Finally, Venturi Wealth Management LLC purchased a new stake in shares of Teva Pharmaceutical Industries during the third quarter worth approximately $60,000. 54.05% of the stock is currently owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Trading Down 2.7 %

Teva Pharmaceutical Industries stock opened at $16.01 on Tuesday. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. Teva Pharmaceutical Industries has a 52 week low of $12.51 and a 52 week high of $22.80. The company has a market capitalization of $18.15 billion, a price-to-earnings ratio of -11.04, a price-to-earnings-growth ratio of 1.44 and a beta of 0.71. The stock has a 50-day moving average price of $19.41 and a 200 day moving average price of $18.46.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. Sell-side analysts anticipate that Teva Pharmaceutical Industries will post 2.5 EPS for the current year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.